Gemcitabine-loaded liposomes: rationale, potentialities and future perspectives

References

• CavallaroGLicciardiMSalmasoSCalicetiPGiammonaGFolate-mediated targeting of polymeric conjugates of gemcitabineInt J Pharm2006307225826916298091
   PubMed Web of Science ®Google Scholar
• ImmordinoMLDosioFCattelLStealth liposomes: review of the basic science, rationale, and clinical applications, existing and potentialInt J Nanomedicine20061329731517717971
   PubMed Web of Science ®Google Scholar
• TrapaniGDenoraNTrapaniALaquintanaVRecent advances in ligand targeted therapyJ Drug Target201220112221942529
   PubMed Web of Science ®Google Scholar
• HeinemannVRole of gemcitabine in the treatment of advanced and metastatic breast cancerOncology200364319120612697958
   PubMed Web of Science ®Google Scholar
• PauwelsBKorstAELardonFVermorkenJBCombined modality therapy of gemcitabine and radiationOncologist2005101345115632251
   PubMed Web of Science ®Google Scholar
• MiniENobiliSCaciagliBLandiniIMazzeiTCellular pharmacology of gemcitabineAnn Oncol200617Suppl 5712
   PubMed Web of Science ®Google Scholar
• LostaoMPMataJFLarrayozIMElectrogenic uptake of nucleosides and nucleoside-derived drugs by the human nucleoside transporter 1 (hCNT1) expressed in Xenopus laevis oocytesFEBS Lett2000481213714010996312
   PubMed Web of Science ®Google Scholar
• UenoHKiyosawaKKaniwaNPharmacogenomics of gemcitabine: can genetic studies lead to tailor-made therapy?Br J Cancer200797214515117595663
   PubMed Web of Science ®Google Scholar
• RitzelMWNgAMYaoSYRecent molecular advances in studies of the concentrative-dependent nucleoside transporter (CNT) family: identification and characterization of novel human and mouse proteins (hCNT3 and mCNT3) broadly selective for purine and pyrimidine nucleosides (system cib)Mol Membr Biol2001181657211396613
   PubMed Web of Science ®Google Scholar
• BhutiaYDHungSWPatelBLovinDGovindarajanRCNT1 expression influences proliferation and chemosensitivity in drug-resistant pancreatic cancer cellsCancer Res20117151825183521343396
   PubMed Web of Science ®Google Scholar
• CoscoDBulottaAVenturaMIn vivo activity of gemcitabine-loaded PEGylated small unilamellar liposomes against pancreatic cancerCancer Chemother Pharmacol20096451009102019263052
   PubMed Web of Science ®Google Scholar
• AllenCDosSNGallagherRControlling the physical behavior and biological performance of liposome formulations through use of surface grafted poly(ethylene glycol)Biosci Rep200222222525012428902
   PubMed Web of Science ®Google Scholar
• KnopKHoogenboomRFischerDSchubertUSPoly(ethylene glycol) in drug delivery: pros and cons as well as potential alternativesAngew Chem Int Ed Engl201049366288630820648499
   PubMed Web of Science ®Google Scholar
• BergmanAMPinedoHMPetersGJDeterminants of resistance to 2′,2′-difluorodeoxycytidine (gemcitabine)Drug Resist Updat200251193312127861
   PubMed Web of Science ®Google Scholar
• BrusaPImmordinoMLRoccoFCattelLAntitumor activity and pharmacokinetics of liposomes containing lipophilic gemcitabine prodrugsAnticancer Res2007271A19519917352232
   PubMed Web of Science ®Google Scholar
• OhhashiSOhuchidaKMizumotoKDown-regulation of deoxycytidine kinase enhances acquired resistance to gemcitabine in pancreatic cancerAnticancer Res2008284B2205221218751396
   PubMed Web of Science ®Google Scholar
• ZhangXYashiroMQiuHEstablishment and characterization of multidrug-resistant gastric cancer cell linesAnticancer Res201030391592120393015
   PubMed Web of Science ®Google Scholar
• GabizonAAShmeedaHZalipskySPros and cons of the liposome platform in cancer drug targetingJ Liposome Res200616317518316952872
   PubMed Web of Science ®Google Scholar
• DasanuCAGemcitabine: vascular toxicity and prothrombotic potentialExpert Opin Drug Saf20087670370618983217
   PubMed Web of Science ®Google Scholar
• ReddyLHCouvreurPNovel approaches to deliver gemcitabine to cancersCurr Pharm Des200814111124113718473859
   PubMed Web of Science ®Google Scholar
• CeliaCCoscoDPaolinoDFrestaMGemcitabine-loaded innovative nanocarriers vs Gemzar: Biodistribution, pharmacokinetic features and in vivo antitumor activityExpert Opin Drug Deliv20118121609162922077480
   PubMed Web of Science ®Google Scholar
• BarenholzYCDoxil® – The first FDA-approved nano-drug: lessons learnedJ Control Release2012160211713422484195
   PubMed Web of Science ®Google Scholar
• PaolinoDCoscoDCilurzoFFrestaMInnovative drug delivery systems for the administration of natural compoundsCurr Bioact Compd20073262277
   Google Scholar
• MuthuMSSinghSTargeted nanomedicines: effective treatment modalities for cancer, AIDS and brain disordersNanomedicine (Lond)20094110511819093899
   PubMed Web of Science ®Google Scholar
• YangFJinCJiangYLiposome based delivery systems in pancreatic cancer treatment: from bench to bedsideCancer Treat Rev201137863364221330062
   PubMed Web of Science ®Google Scholar
• TorchilinVAntibody-modified liposomes for cancer chemotherapyExpert Opin Drug Del20085910031025
   PubMed Web of Science ®Google Scholar
• YanXScherphofGLKampsJALiposome opsonizationJ Liposome Res2005151–210913916194930
   PubMed Web of Science ®Google Scholar
• DecuzziPCausaFFerrariMNettiPAThe effective dispersion of nanovectors within the tumor microvasculatureAnn Biomed Eng200634463364116568349
   PubMed Web of Science ®Google Scholar
• CoscoDPaolinoDMuzzalupoRNovel PEG-coated niosomes based on bola-surfactant as drug carriers for 5-fluorouracilBiomed Microdevices20091151115112519507033
   PubMed Web of Science ®Google Scholar
• PasutGVeroneseFMPEGylation for improving the effectiveness of therapeutic biomoleculesDrugs Today (Barc)200945968769519956810
   PubMed Web of Science ®Google Scholar
• VeroneseFMPasutGPEGylation, successful approach to drug deliveryDrug Discov Today200510211451145816243265
   PubMed Web of Science ®Google Scholar
• GabizonAShmeedaHBarenholzYPharmacokinetics of pegylated liposomal doxorubicin: review of animal and human studiesClin Pharmacokinet200342541943612739982
   PubMed Web of Science ®Google Scholar
• NiuGCogburnBHughesJPreparation and characterization of doxorubicin liposomesMethods Mol Biol201062421121920217598
   PubMedGoogle Scholar
• DugganSTKeatingGMPegylated liposomal doxorubicin: a review of its use in metastatic breast cancer, ovarian cancer, multiple myeloma and AIDS-related Kaposi’s sarcomaDrugs201171182531255822141391
   PubMed Web of Science ®Google Scholar
• CelanoMCalvagnoMGBulottaSCytotoxic effects of gemcitabine-loaded liposomes in human anaplastic thyroid carcinoma cellsBMC Cancer200446315363094
   PubMed Web of Science ®Google Scholar
• CalvagnoMGCeliaCPaolinoDEffects of lipid composition and preparation conditions on physical-chemical properties, technological parameters and in vitro biological activity of gemcitabine-loaded liposomesCurr Drug Deliv2007418910117269921
   PubMedGoogle Scholar
• CastelliFRaudinoAFrestaMA mechanistic study of the permeation kinetics through biomembrane models: gemcitabine-phospholipid bilayer interactionJ Colloid Interface Sci2005285111011715797403
   PubMed Web of Science ®Google Scholar
• LiangWLevchenkoTKhawBATorchilinVATP-containing immunoliposomes specific for cardiac myosinCurr Drug Deliv2004111716305365
   PubMedGoogle Scholar
• ImmordinoMLBrusaPRoccoFArpiccoSCerutiMCattelLPreparation, characterization, cytotoxicity and pharmacokinetics of liposomes containing lipophilic gemcitabine prodrugsJ Control Release2004100333134615567500
   PubMed Web of Science ®Google Scholar
• CouvreurPStellaBReddyLHSqualenoyl nanomedicines as potential therapeuticsNano Lett20066112544254817090088
   PubMed Web of Science ®Google Scholar
• ReddyLHDubernetCMouelhiSLMarquePEDesmaeleDCouvreurPA new nanomedicine of gemcitabine displays enhanced anticancer activity in sensitive and resistant leukemia typesJ Control Release20071241–2202717878060
   PubMed Web of Science ®Google Scholar
• PiliBReddyLHBourgauxCLepetre-MouelhiSDesmaeleDCouvreurPLiposomal squalenoyl–gemcitabine: formulation, characterization and anticancer activity evaluationNanoscale2010281521152620820745
   PubMed Web of Science ®Google Scholar
• IshidaTHaradaMWangXYIchiharaMIrimuraKKiwadaHAccelerated blood clearance of PEGylated liposomes following preceding liposome injection: effects of lipid dose and PEG surface-density and chain length of the first-dose liposomesJ Control Release2005105330531715908032
   PubMed Web of Science ®Google Scholar
• DamsETLavermanPOyenWJAccelerated blood clearance and altered biodistribution of repeated injections of sterically stabilized liposomesJ Pharmacol Exp Ther200029231071107910688625
   PubMed Web of Science ®Google Scholar
• IshidaTKiwadaHAccelerated blood clearance (ABC) phenomenon upon repeated injection of PEGylated liposomesInt J Pharm20083541–2566218083313
   PubMed Web of Science ®Google Scholar
• PaolinoDCoscoDMolinaroRCeliaCFrestaMSupramolecular devices to improve the treatment of brain diseasesDrug Discov Today2011167–831132421335100
   PubMed Web of Science ®Google Scholar
• IshiharaTMaedaTSakamotoHEvasion of the accelerated blood clearance phenomenon by coating of nanoparticles with various hydrophilic polymersBiomacromolecules201011102700270620795699
   PubMed Web of Science ®Google Scholar
• XuHWangKQDengYHChen daWEffects of cleavable PEG-cholesterol derivatives on the accelerated blood clearance of PEGylated liposomesBiomaterials201031174757476320303164
   PubMed Web of Science ®Google Scholar
• PasutGCanalFDalla ViaLArpiccoSVeroneseFMSchiavonOAntitumoral activity of PEG-gemcitabine prodrugs targeted by folic acidJ Control Release2008127323924818346806
   PubMed Web of Science ®Google Scholar
• PaolinoDCoscoDRacanicchiLGemcitabine-loaded PEGylated unilamellar liposomes vs GEMZAR: biodistribution, pharmacokinetic features and in vivo antitumor activityJ Control Release2010144214415020184929
   PubMed Web of Science ®Google Scholar
• VonoMCoscoDCeliaCIn vitro evaluation of the activity of gemcitabine-loaded pegylated unilamellar liposomes against papillary thyroid cancer cellsThe Open Drug Delivery Journal201045562
   Google Scholar
• DanNEffect of liposome charge and PEG polymer layer thickness on cell-liposome electrostatic interactionsBiochim Biophys Acta20021564234334812175916
   PubMed Web of Science ®Google Scholar
• BorowikTWiderakKUgorskiMLangnerMCombined effect of surface electrostatic charge and poly(ethyl glycol) on the association of liposomes with colon carcinoma cellsJ Liposome Res2005153–419921316393911
   PubMed Web of Science ®Google Scholar
• CeliaCCalvagnoMGPaolinoDImproved in vitro anti-tumoral activity, intracellular uptake and apoptotic induction of gemcitabine-loaded pegylated unilamellar liposomesJ Nanosci Nanotechnol2008842102211318572621
   PubMed Web of Science ®Google Scholar
• CeliaCMalaraNTerraccianoRLiposomal delivery improves the growth-inhibitory and apoptotic activity of low doses of gemcitabine in multiple myeloma cancer cellsNanomedicine20084215516618430611
   PubMed Web of Science ®Google Scholar
• BornmannCGraeserREsserNA new liposomal formulation of gemcitabine is active in an orthotopic mouse model of pancreatic cancer accessible to bioluminescence imagingCancer Chemother Pharmacol200861339540517554540
   PubMed Web of Science ®Google Scholar
• JantscheffPZiroliVEsserNAnti-metastatic effects of liposomal gemcitabine in a human orthotopic LNCaP prostate cancer xenograft modelClin Exp Metastasis200926898199219784785
   PubMed Web of Science ®Google Scholar
• MoogRBurgerAMBrandlMChange in pharmacokinetic and pharmacodynamic behavior of gemcitabine in human tumor xenografts upon entrapment in vesicular phospholipid gelsCancer Chemother Pharmacol200249535636611976829
   PubMed Web of Science ®Google Scholar
• KimIYKangYSLeeDSAntitumor activity of EGFR targeted pH-sensitive immunoliposomes encapsulating gemcitabine in A549 xenograft nude miceJ Control Release20091401556019616596
   PubMed Web of Science ®Google Scholar
• CelanoMSchenoneSCoscoDCytotoxic effects of a novel pyrazolopyrimidine derivative entrapped in liposomes in anaplastic thyroid cancer cells in vitro and in xenograft tumors in vivoEndocr Relat Cancer200815249951018509002
   PubMed Web of Science ®Google Scholar
• Drulis-KawaZDorotkiewicz-JachALiposomes as delivery systems for antibioticsInt J Pharm20103871–218719819969054
   PubMed Web of Science ®Google Scholar
• RobertNJVogelCLHendersonICThe role of the liposomal anthracyclines and other systemic therapies in the management of advanced breast cancerSemin Oncol2004316 Suppl 1310614615717740
   PubMed Web of Science ®Google Scholar
• InjacRStrukeljBRecent advances in protection against doxorubicin-induced toxicityTechnol Cancer Res Treat20087649751619044329
   PubMed Web of Science ®Google Scholar
• ColomerRWhat is the best schedule for administration of gemcitabine-taxane?Cancer Treat Rev200531Suppl 4S23S2816360544
   PubMed Web of Science ®Google Scholar
• HarasymTOTardiPGHarasymNLHarviePJohnstoneSAMayerLDIncreased preclinical efficacy of irinotecan and floxuridine coencapsulated inside liposomes is associated with tumor delivery of synergistic drug ratiosOncol Res200716836137417913044
   PubMed Web of Science ®Google Scholar
• TardiPGGallagherRCJohnstoneSCoencapsulation of irinotecan and floxuridine into low cholesterol-containing liposomes that coordinate drug release in vivoBiochim Biophys Acta20071768367868717208196
   PubMed Web of Science ®Google Scholar
• TardiPGDos SantosNHarasymTODrug ratio-dependent antitumor activity of irinotecan and cisplatin combinations in vitro and in vivoMol Cancer Ther2009882266227519671743
   PubMed Web of Science ®Google Scholar
• CoscoDPaolinoDMaiuoloJRussoDFrestaMLiposomes as multicompartmental carriers for multidrug delivery in anticancer chemotherapyDrug Deliv Transl Res201116675
   Web of Science ®Google Scholar
• CoscoDPaolinoDCilurzoFCasaleFFrestaMGemcitabine and tamoxifen-loaded liposomes as multidrug carriers for the treatment of breast cancer diseasesInt J Pharm20124221–222923722093954
   PubMed Web of Science ®Google Scholar
• ZhengAKallioAHärkönenPTamoxifen-induced rapid death of MCF-7 breast cancer cells is mediated via extracellularly signal-regulated kinase signaling and can be abrogated by estrogenEndocrinology200714862764277717363451
   PubMed Web of Science ®Google Scholar
• BrauchHJordanVCTargeting of tamoxifen to enhance antitumor action for the treatment and prevention of breast cancer: the ‘ personalised’ approach?Eur J Cancer200945132274228319592233
   PubMed Web of Science ®Google Scholar
• PaolinoDCoscoDLicciardiMGiammonaGFrestaMCavallaroGPolyaspartyl hydrazide copolymer-based supramolecular vesicular aggregates as delivery devices for anticancer drugsBiomacromolecules2008941117113018307306
   PubMed Web of Science ®Google Scholar
• LicciardiMPaolinoDCeliaCGiammonaGCavallaroGFrestaMFolate-targeted supramolecular vesicular aggregates based on polyaspartyl-hydrazide copolymers for the selective delivery of antitumoral drugsBiomaterials201031287340735420609469
   PubMed Web of Science ®Google Scholar